Targeting STAT3 signaling in kidney disease

Area of Science:

• Molecular Biology
• Cellular Signaling
• Nephrology

Background:

• The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway regulates cellular responses.
• Signal transducer and activator of transcription 3 (STAT3) is implicated in cancers and autoimmune disorders.
• STAT3's role in kidney disease progression is a recent focus, despite known benefits of its inhibition in models.

Purpose of the Study:

• To review the detrimental role of dysregulated STAT3 activation in kidney diseases.
• To summarize the progress in treating kidney diseases via pharmacological STAT3 inhibition.

Main Methods:

• Review of existing literature on STAT3 signaling in kidney disease.
• Analysis of genetic studies demonstrating benefits of STAT3 inhibition.
• Examination of pharmacological STAT3 inhibitors developed for cancer and tested in kidney disease models.

Main Results:

• Dysregulated STAT3 activation contributes to various kidney diseases.
• Genetic studies confirm beneficial effects of STAT3 inhibition in kidney disease models.
• Limited but growing number of STAT3 inhibitors have been evaluated in kidney disease.

Conclusions:

• STAT3 is a key mediator in the pathogenesis of kidney diseases.
• Pharmacological inhibition of STAT3 represents a potential therapeutic strategy for kidney disease.
• Further research and clinical translation of STAT3 inhibitors are warranted for kidney disease treatment.